Proactiveinvestors recommends
Additional Information
Market: ASX
Sector: Pharmaceuticals & Biotechnology
EPIC: CIR
Latest Price: A$0.50  (0,00%)
52-week High: A$0.77
52-week Low: A$0.44
Market Cap: A$23.20M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Watchlist/Portfolio

Add to watchlist:

Only registered members can add into watchlist !

Register here !
Circadian Technologies
www.circadian.com.au

Circadian Technologies Limited (ASX: CIR) is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses. Circadian owns an extensive portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating tumour blood supply. These programs are conducted through Vegenics Ltd, a wholly-owned subsidiary of Circadian.

Full Circadian Technologies profile here
Pdf

Circadian Technologies CEO Robert Klupacs to present at Merriam Curhan Ford Investor Summit in NYC

10th Nov 2009, 2:46 pm

Victorian-based Circadian Technologies (ASX: CIR) a developer of novel, biological-based treatments for cancer has advised that Robert Klupacs, CEO and Managing Director will be presenting at Merriman Curhan Ford’s 6th annual Investor Summit in New York City on November 10, 2009.

The Merriam Curhan Ford conference is usually attended by hundreds of institutional investors.

Ciradian is developing antibody therapies to treat cancer - a major global opportunity for the Australian listed company.

The company has established partner programs with leading international players in their fields including:

- ImClone Systems Inc (recently acquired by Eli Lilly & Co) (NYSE:LLY) – developing anticancer drug (out-licensed)
- Healthscope Limited (ASX:HSP) – developing cancer diagnostic test (out-licensed)
- Teva Biopharmaceuticals (USA) – VEGF-C IP (in-licensed)

CIR has an increasing number of revenue generating research reagent partnerships:
- R&D Systems, Millipore, Reliatech GmbH, Perkin Elmer (out-licensed)

Major Milestones - 2010

VGX-100 cancer drug development program
– Animal tumour model evaluation:  H1 2010
– FDA pre-IND review: H1 2010
– Toxicology completion: H1 2010
– IND Filing: H" 2011

IND filing: IMC-3C5 for cancer: H2 2010
(ImClone/Eli Lilly partner)

CUP molecular diagnostic: H2 2010
– Market launch

ANP (listed investment) milestone Q1 2010
– Antisense Therapeutics’ (ASX:ANP)
partner Teva to advise of decision to
progress MS treatment ATL/TV 1102
into late stage clinical studies

- Resolution of unlicensed gene therapy H2 2010
development by third parties

Presenting at the investor summit, Circadian will showcase its investment characteristics:

Therapeutic antibodies
– Major focus of big pharma
– High value early stage deal opportunities and M&A opportunities

Deep diverse product pipeline
– Potential multi-million dollar royalties
– Royalty flows possible <12 months

Angiogenesis - significant product opportunity validated

IP Position

Circadian has a dominant and protected Intellectual Property (IP) position. The company has granted IP rights in major territories to VEGF-C/D proteins and VEGFR-3 and blockers, with applications in cancer and certain other diseases.  IP rights over product candidates extend beyond 2020.  Further strategic IP filings are being made to extend patent life.  The company has over 500 granted and pending patents worldwide 

The company has an inherent strong drug development expertise and management.  CEO Robert Klupacs has over 22 years biotech experience. Extensive history of industry deals including Sanofi, Baxter, Aventis, Pharmacia, Novartis, Alexion and Pfizer.

Strong financial position

Intriguingly for investors, Circadian has cash holdings of $35.5m, also owns listed investments worth $9.5m.  Issued capital is only 46.39m shares on issue.  Yet, market capitalisation is only $33m - on a share price of $0.71.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.